In breast and endometrial cancers, autocrine GH had earlier been shown to blunt the efficacy of several chemotherapy treatments (mitomycin-C, doxorubicin, cisplatin, arsenic trioxide, ruxolitinib) wherein the effects were ascribed to a suppressed apoptosis (23, 62–64). The gene discussed is GH1; the disease is endometrial cancer.